Crewe Advisors’s Inozyme Pharma INZY Stock Holding History

Crewe Advisors’s Portfolio INZY Stock Details INZY Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q4	–	Sell	-163	Closed	–	–	1145
2022 Q3	$0	Hold	163	–	–	﹤0.01%	1262
2022 Q2	$1K	Buy	+163	New	+$709	﹤0.01%	1075

Other funds holding INZY

Sofinnova Investments Menlo Park, California $2.63B AUM 117.41% 1-Year Est. Return

Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return

Adage Capital Partners

Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return

VR Adviser New York $2.68B AUM 422.73% 1-Year Est. Return

Pivotal bioVenture Partners Investment Advisor San Francisco, California $280M AUM 181.4% 1-Year Est. Return

NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return

CHI Advisors New York $252M AUM 56.99% 1-Year Est. Return

Sphera Funds Management Tel Aviv, Israel $630M AUM 108.65% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Crewe Advisors's INZY Position: Q4 2022 in Review

Crewe Advisors sold out of Inozyme Pharma (INZY) in Q4 2022, closing a stake of 163 shares.

Crewe Advisors first reported a position in INZY in Q2 2022 and held it in 2 quarters. The position peaked at $1K in Q2 2022. 37 funds tracked by Wall St. Rank hold INZY as of Q4 2022.

Crewe Advisors reported no remaining Inozyme Pharma position as of Q4 2022 after selling out during the quarter.
Crewe Advisors sold 163 Inozyme Pharma shares in Q4 2022.
Crewe Advisors first reported a position in Inozyme Pharma in Q2 2022 and held it in 2 quarters.
Crewe Advisors's Inozyme Pharma position peaked at $1K in Q2 2022.
37 funds tracked by Wall St. Rank held Inozyme Pharma as of Q4 2022.

Based on Crewe Advisors's 13F filing for Q4 2022, filed 8 Feb 2023.